The Role of Hepcidin Level as a Predictor for Mortality in Cancer Patients with Sepsis

Ngakan Ketut Wira Suastika; Ketut  Suega

doi:10.3889/oamjms.2022.11008

Authors

Ngakan Ketut Wira Suastika Department of Internal Medicine, Faculty of Medicine, Udayana University, Udayana University Hospital, Bali, Indonesia https://orcid.org/0000-0003-2306-101X
Ketut Suega Department of Internal Medicine, Faculty of Medicine, Udayana University, Sanglah General Hospital, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.11008

Keywords:

C-reactive protein, Hepcidin, Malignancy, Sepsis, Survival

Abstract

BACKGROUND: Sepsis is the most common cause of death in hospitalized cancer patients. Iron metabolism is one system that is strongly influenced by severe infectious and inflammatory conditions.

AIM: This study aims to determine the difference in survival based on hepcidin levels in surviving and non-surviving cancer patients with sepsis.

METHODS: This study is a cohort study in solid and hematological cancer patients with sepsis aged 18 years and older who were hospitalized from February to June 2022. The criteria for sepsis are the presence of infection accompanied by a Sequential Organ Failure Assessment (SOFA) score of two points or more. A total of 40 samples were included in this study.

RESULTS: We found different survival curves in subjects with high hepcidin levels compared to subjects with low hepcidin levels. The hazard ratio (HR) of hepcidin levels was 7.28 (95% confidence interval (CI) 2.35–22.55), p<0.001. In multivariate analysis, hepcidin levels had an adjusted HR of 7.91 (2.51–24.91), p < 0.001.

CONCLUSIONS: From the results of this study, it can be concluded that cancer patients with sepsis who have high hepcidin levels have lower survival than patients with low hepcidin levels at 28-day follow-up.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-10. https://doi.org/10.1001/jama.2016.0287 PMid:26903338

Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy. Chest. 2006;129(6):1432-40. https://doi.org/10.1378/chest.129.6.1432 PMid:16778259

Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian D, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26(11):2284-99. https://doi.org/10.1038/s41418-019-0299-4 PMid:30737476

Liu Q, Wu J, Zhang X, Wu X, Zhao Y, Ren J. Iron homeostasis and disorders revisited in the sepsis. Free Radic Bio Med. 2021;165:1-13. https://doi.org/10.1016/j.freeradbiomed.2021.01.025 PMid:33486088

Docherty AB, Turgeon AF, Walsh TS. Best practice in critical care: Anaemia in acute and critical illness. Transfus Med. 2018;28(2):181-9. https://doi.org/10.1111/tme.12505 PMid:29369437

Jiang Y, Jiang FQ, Kong F, An MM, Jin BB, Cao D, et al. Inflammatory anemia-associated parameters are related to 28-day mortality in patients with sepsis admitted to the ICU: A preliminary observational study. Ann Intensive Care. 2019;9(1):67. https://doi.org/10.1186/s13613-019-0542-7 PMid:31183575

Lan P, Pan KH, Wang SJ, Shi QC, Yu YX, Fu Y, et al. High serum iron level is associated with increased mortality in patients with sepsis. Sci Rep. 2018;8(1):11072. https://doi.org/10.1038/s41598-018-29353-2 PMid: 30038422

Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015;15(8):500-10. https://doi.org/10.1038/nri3863 PMid:26160612

Aron AT, Heffern MC, Lonergan ZR, Vander Wal MN, Blank BR, Spangler B, et al. In vivo bioluminescence imaging of labile iron accumulation in a murine model of acinetobacter baumannii infection. Proc Natl Acad Sci U S A. 2017;114(48):12669-74. https://doi.org/10.1073/pnas.1708747114 PMid:29138321

Stefanova D, Raychev A, Arezes J, Ruchala P, Gabayan V, Skurnik M, et al. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. Blood. 2017;130(3):245-57. https://doi.org/10.1182/blood-2017-03-772715 PMid:28465342

Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: Regulation of mammalian iron metabolism. Cell. 2010;142(1):24-38. https://doi.org/10.1016/j.cell.2010.06.028 PMid:20603012

Vokurka M, Krijt J, Vavrova J, Necas E. Hepcidin expression in the liver of mice with implanted tumour reacts to iron deficiency, inflammation and erythropoietin administration. Folia Biol (Praha). 2011;57(6):248-54. PMid:22264719

Ward DG, Roberts K, Brookes MJ, Joy H, Martin A, Ismail T, et al. Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol. 2008;14(9):1339-45. https://doi.org/10.3748/wjg.14.1339 PMid:18322945

Kamai T, Tomosugi N, Abe H, Arai K, Yoshida KI. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer. 2009;9:270. https://doi.org/10.1186/1471-2407-9-270 PMid:19656379

Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL, et al. Hepcidin, anaemia, and prostate cancer. BJU Int. 2011;107(4):678-9. https://doi.org/10.1111/j.1464-410X.2011.10108.x PMid:21276178